Extracellular matrix hydrogel as growth factor delivery system for prolonged release and enhanced effect of a novel engineered HGF mimic in a small animal model of myocardial infarction

摘要

Here, we demonstrate in vivo potency of a novel engineered HGF mimic, opening the potential to use this protein, in conjunction with an ECM hydrogel, as an injectable therapy for MI. We have shown this HGF mimic can be sequestered by an ECM hydrogel via interactions with sulfated sugars in the biomaterial; small animal studies indicate delivery of the HGF mimic with PPM may provide benefit post-MI by increasing neovascularization, reducing interstitial fibrosis, and preserving LV geometry. This HGF mimic and ECM hydrogel are a promising therapeutic combination with potential benefits of reduced cost, improved stability, and improved delivery compared to treatment with rh-HGF. Future studies evaluating dose response will also allow further investigation of the mechanisms by which positive outcomes are achieved and optimize therapeutic benefit.